Partner Therapeutics (PTx) is a Boston, MA–based integrated commercial-stage biotech led by CEO Robert Mulroy. The company focuses on development and commercialization of therapeutics across the full range of cancer therapy, from primary treatments to supportive care. PTx intends to build its product portfolio through the acquisition of programs that can deliver improved health and economic outcomes. The business plans to use new funding to launch and build a pipeline of oncology programs and to support development and commercial operations. The company emphasizes both clinical development and commercial capabilities as it expands its oncology offerings. Current financing activity reflects efforts to fund near-term growth and portfolio expansion.

Total raised

$60M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2018